CONSOLIDATED AND COMBINED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) $ in Millions		Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Accumulated Other Comprehensive Income (Loss)	Additional Paid-in Capital	Accumulated Deficit	Net Former Parent Investment	Net Former Parent Investment Cumulative Effect, Period of Adoption, Adjustment
Common stock, shares beginning balance (in shares) at Dec. 30, 2017				0
Common stock, shares beginning balance at Dec. 30, 2017		$ 1,215	$ 2	$ 0	$ (42)	$ 0	$ 0	$ 1,257	$ 2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to Covetrus		$ 101						101
Accounting Standards Update [Extensible List]		us-gaap:AccountingStandardsUpdate201409Member
Net increase in Former Parent investment		$ 174						174
Series A preferred stock dividend		0
Other comprehensive income (loss)		(40)			(40)
Common stock, shares outstanding (in shares) at Dec. 29, 2018				0
Common stock, shares ending balance at Dec. 29, 2018		1,452		$ 0	(82)	0	0	1,534
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to Covetrus	[1]	(980)					(1,001)	21
Dividend to Former Parent		(1,174)				(21)		(1,153)
Issuance of shares at Separation (including Share Sale investors) (in shares)				71,693,426
Issuance of shares at Separation (including Share Sale investors)		0		$ 1		566		(567)
Issuance of shares in connection with the Acquisition (in shares)	[2]			39,742,089
Issuance of shares in connection with the Acquisition	[2]	1,772				1,772
Shares canceled (in shares)	[2]			(700,400)
Shares canceled	[2]	(30)				(30)
Issuance of shares in connection with share-based compensation plans				885,392
Issuance of shares in connection with share-based compensation plans		5				5
Net increase in Former Parent investment		172						172
Share-based compensation		46				46
Deferred tax impact of acquisition of non-controlling interest		(7)						(7)
Series A preferred stock dividend		0
Other		1				1
Other comprehensive income (loss)		$ (4)			(4)
Common stock, shares outstanding (in shares) at Dec. 31, 2019		111,620,507		111,620,507
Common stock, shares ending balance at Dec. 31, 2019		$ 1,253		$ 1	(86)	2,339	(1,001)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to Covetrus		(19)					(19)	0
Change in fair value of redeemable securities		(6)				(6)
Issuance of shares in connection with share-based compensation plans				1,793,394
Issuance of shares in connection with share-based compensation plans		10				10
Share-based compensation		40				40
Series A preferred stock dividend		(7)					(7)
Conversion of Series A Preferred stock (in shares)				22,604,063
Conversion of Series A preferred stock		246				246
Other comprehensive income (loss)		$ 20			20
Common stock, shares outstanding (in shares) at Dec. 31, 2020		136,017,964		136,017,964
Common stock, shares ending balance at Dec. 31, 2020		$ 1,537		$ 1	$ (66)	$ 2,629	$ (1,027)	$ 0

[1] (a) Net income earned from January 1, 2019 through February 7, 2019 is attributed to the Former Parent as it was the sole shareholder prior to February 7, 2019

[2] (b) See Note 3 - Business Acquisitions